CME Institute

Home | About Us | Mission Statement | All CME Activities | MyCME | CME Facebook | CME Twitter

JCP

Home | About JCP | Subscribe | Archive | Information for Authors | Information for Reviewers | Information for Advertisers | CNS Job Market | Customer Service | JCP Facebook | JCP Twitter

PCC

Home | About PCC | Register | Archive | Information for Authors | Information for Reviewers | PCC Facebook | PCC Twitter

Help

FAQ | About Psychiatrist.com | Terms of use | Privacy policy

magnifying glass for search

  • magnifying glass for search
  • Advanced Search

Login

Login  
Login | Login Help | Register | Subscribe
  Subscribe to JCP | Elerts

Quick Links

Font: A | A | A

Top

Free PDF

Reprints

JCP Weekly
Table of Contents

Facebook ShareShare

twitter shareTweet This

envelope iconEmail a link

Related ►

Related Articles

[X]

<div id="freepromo">Enjoying this free article from JCP? You can get access to many more articles and the chance to earn CME credit by <a href="/pages/register.aspx">registering for a free account</a>.</div> <p class="frontmatter-fieldnotes disclaimernew" style="margin-bottom:15px;">This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s <a href="/pages/termsofuse.aspx" target="_blank">Terms & Conditions</a>.</p> <div>
<div id="_idContainer000" class="weekly">

<p style="text-align: right; margin: 10px 0 5px; font-size: 10em;">See reply by <a href="/JCP/article/Pages/dr-andrade-replies.aspx" target="_top">Andrade</a></span></p>

<p class="ltrs-br-ltr-br-title"><span class="bold">Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit</span></p>
<p class="ltrs-br-ltr-br-body-text"><span class="semibold">To the Editor:</span> Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30–300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.<span class="htm-cite"><a href="#ref1">1</a></span></p>
<p class="ltrs-br-ltr-br-body-text">First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (<a href="https://clinicaltrials.gov/ct2/show/NCT01738282" target="_blank"><span class="hyperlink">NCT01738282</span></a>; 320 patients, as with Bacloville), was negative (see Braillon et al<span class="htm-cite"><a href="#ref2">2</a></span>).</p>
<p class="ltrs-br-ltr-br-body-text">Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,<span class="htm-cite"><a href="#ref3">3</a></span> he overlooked the evidence we provided indicating that the Bacloville article<span class="htm-cite"><a href="#ref4">4</a></span> was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”</p>
<p class="ltrs-br-ltr-br-body-text">Third, expecting that a reduction of, at best, a drink per day versus placebo, if confirmed and if possible in the long term in dependent users, could modify clinically relevant outcomes such as quality of life, morbidity, and mortality when there are already harms such as liver disease flies in the face of common sense.</p>
<p class="ltrs-br-ltr-br-body-text">Finally, the 2-fold increase in mortality with baclofen in Bacloville (highest dose allowed, 180 mg/d) was not significant, the series being short, but was in line with a large-scale pharmacoepidemiologic study in a real-life setting that suggested a dose-dependent increase in mortality with baclofen versus acamprosate and naltrexone.<span class="htm-cite"><a href="#ref5">5</a></span></p>
<p class="ltrs-br-ltr-br-body-text">Individualizing treatment is the cornerstone of care, even more so for patients with substance use disorders, but it is about psychosocial care, to which access must be improved.<span class="htm-cite"><a href="#ref6">6</a></span> Promoting off-label use of high doses of baclofen worldwide in a core clinical journal is not serving patients’ interests. In our humble opinion, France will remain the only country worldwide where baclofen has a marketing approval for the following reasons: (<span class="italic">a</span>) the French pharmaceutical company deliberately avoided the usual European marketing approval process and cannot expect an authorization by the US Food and Drug Administration, which relies on robust criteria (abstinence, no heavy drinking days, biochemical markers of alcohol use), and (<span class="italic">b</span>) the director of the French medicines agency granted a marketing approval despite the Special Scientific Committee’s conclusion that the benefits/harms ratio was negative. The Chairman of the Committee commented that he “well understood that the benefit-risk assessment [of baclofen] was only one element, among others [behind the decision].”<span class="htm-cite"><a href="#ref2">2</a></span></p>
<p class="references_references-heading"><span class="bold">REFERENCES</span></p>
<p class="references-references-text-1-9"><a name="ref1"></a><span class="htm-ref"> 1. </span>Andrade C. Individualized, high-dose baclofen for reduction in alcohol intake in persons with high levels of consumption. <span class="italic">J Clin Psychiatry</span>. 2020;81(4):20f13606. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32757504&dopt=Abstract" target="_blank"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.4088/JCP.20f13606" target="_blank"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-1-9"><a name="ref2"></a><span class="htm-ref"> 2. </span>Braillon A, Naudet F, Cristea IA, et al. Baclofen and alcohol use disorders: breakthrough or great white elephant? <span class="italic">Alcohol Alcohol</span>. 2020;55(1):49–50. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31761929&dopt=Abstract" target="_blank"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1093/alcalc/agz083" target="_blank"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-1-9"><a name="ref3"></a><span class="htm-ref"> 3. </span>Naudet F, Braillon A, Cristea IA, et al. Restoring the Bacloville trial: efficacy and harms [published online ahead of print May 4, 2020]. <span class="italic">Addiction</span>. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32364248&dopt=Abstract" target="_blank"><span class="pubmed-crossref">PubMed</span></a></p>
<p class="references-references-text-1-9"><a name="ref4"></a><span class="htm-ref"> 4. </span>Rigal L, Sidorkiewicz S, Tréluyer J-M, et al. Titrated baclofen for high-risk alcohol consumption: a randomized placebo-controlled trial in out-patients with 1-year follow-up. <span class="italic">Addiction</span>. 2020;115(7):1265–1276. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31833590&dopt=Abstract" target="_blank"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1111/add.14927" target="_blank"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-1-9"><a name="ref5"></a><span class="htm-ref"> 5. </span>Chaignot C, Zureik M, Rey G, et al. Risk of hospitalisation and death related to baclofen for alcohol use disorders: comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France. <span class="italic">Pharmacoepidemiol Drug Saf</span>. 2018;27(11):1239–1248. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=30251424&dopt=Abstract" target="_blank"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1002/pds.4635" target="_blank"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-1-9"><a name="ref6"></a><span class="htm-ref"> 6. </span>Volpicelli JR. Alcohol abuse and alcoholism: an overview. <span class="italic">J Clin Psychiatry</span>. 2001;62(suppl 20):4–10. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11584874&dopt=Abstract" target="_blank"><span class="pubmed-crossref">PubMed</span></a></p>
<p class="ltrs-br-ltr-br-author"><span class="bold">Alain Braillon, MD, PhD</span><span class="superscript">a</span></p>
<p class="ltrs-br-ltr-br-author"><a href="mailto:braillon.alain@gmail.com">braillon.alain@gmail.com</a></p>
<p class="ltrs-br-ltr-br-author"><span class="bold">Florian Naudet, MD, PhD</span><span class="superscript">b</span></p>
<p class="end-matter"><span class="superscript">a</span>Retired senior consultant, Amiens, France.</p>
<p class="end-matter"><span class="superscript">b</span>Centre Hospitalier Universitaire and Inserm, Centre d’Investigation Clinique, Rennes, France</p>
<p class="end-matter"><span class="bold-italic">Published online:</span> January 12, 2021.</p>
<p class="end-matter"><span class="bold-italic">Potential conflicts of interest:</span> Drs Braillon and Naudet note that they are included in Jeanne Lenzer’s list of industry independent experts (<a href="https://jeannelenzer.com/list-independent-experts" target="_blank"><span class="hyperlink">https://jeannelenzer.com/list-independent-experts</span></a>).</p>
<p class="end-matter"><span class="bold-italic">Funding/support:</span> None.</p>
<p class="front-matter"><span class="italic">J Clin Psychiatry 2021;82(1):20lr13642</span></p>
<p class="front-matter-rule"><span class="bold-italic">To cite:</span> Braillon A, Naudet F. Baclofen, a French exception, seriously harms alcohol use disorder patients without benefit. <span class="italic">J Clin Psychiatry</span>. 2021;82(1):20lr13642.</p>
<p class="doi-line"><span class="bold-italic">To share: </span>https://doi.org/<span class="doi">10.4088/JCP.20lr13642</span></p>
<p class="end-matter">© <span class="italic">Copyright 2021 Physicians Postgraduate Press, Inc.</span></p>
</div>
</div>
Manage Subscriptions
/_layouts/images/ReportServer/Manage_Subscription.gif
/JCP/article/_layouts/ReportServer/ManageSubscriptions.aspx?list={ListId}&ID={ItemId}
0x80
0x0
FileType
rdl
350
Manage Data Sources
/JCP/article/_layouts/ReportServer/DataSourceList.aspx?list={ListId}&ID={ItemId}
0x0
0x20
FileType
rdl
351
Manage Shared Datasets
/JCP/article/_layouts/ReportServer/DatasetList.aspx?list={ListId}&ID={ItemId}
0x0
0x20
FileType
rdl
352
Manage Parameters
/JCP/article/_layouts/ReportServer/ParameterList.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rdl
353
Manage Processing Options
/JCP/article/_layouts/ReportServer/ReportExecution.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rdl
354
Manage Cache Refresh Plans
/JCP/article/_layouts/ReportServer/CacheRefreshPlanList.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rdl
355
View Report History
/JCP/article/_layouts/ReportServer/ReportHistory.aspx?list={ListId}&ID={ItemId}
0x0
0x40
FileType
rdl
356
View Dependent Items
/JCP/article/_layouts/ReportServer/DependentItems.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rsds
350
Edit Data Source Definition
/JCP/article/_layouts/ReportServer/SharedDataSource.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rsds
351
View Dependent Items
/JCP/article/_layouts/ReportServer/DependentItems.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
smdl
350
Manage Clickthrough Reports
/JCP/article/_layouts/ReportServer/ModelClickThrough.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
smdl
352
Manage Model Item Security
/JCP/article/_layouts/ReportServer/ModelItemSecurity.aspx?list={ListId}&ID={ItemId}
0x0
0x2000000
FileType
smdl
353
Regenerate Model
/JCP/article/_layouts/ReportServer/GenerateModel.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
smdl
354
Manage Data Sources
/JCP/article/_layouts/ReportServer/DataSourceList.aspx?list={ListId}&ID={ItemId}
0x0
0x20
FileType
smdl
351
Load in Report Builder
/JCP/article/_layouts/ReportServer/RSAction.aspx?RSAction=ReportBuilderModelContext&list={ListId}&ID={ItemId}
0x0
0x2
FileType
smdl
250
Edit in Report Builder
/_layouts/images/ReportServer/EditReport.gif
/JCP/article/_layouts/ReportServer/RSAction.aspx?RSAction=ReportBuilderReportContext&list={ListId}&ID={ItemId}
0x0
0x4
FileType
rdl
250
Edit in Report Builder
/JCP/article/_layouts/ReportServer/RSAction.aspx?RSAction=ReportBuilderDatasetContext&list={ListId}&ID={ItemId}
0x0
0x4
FileType
rsd
250
Manage Caching Options
/JCP/article/_layouts/ReportServer/DatasetCachingOptions.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rsd
350
Manage Cache Refresh Plans
/JCP/article/_layouts/ReportServer/CacheRefreshPlanList.aspx?list={ListId}&ID={ItemId}&IsDataset=true
0x0
0x4
FileType
rsd
351
Manage Data Sources
/JCP/article/_layouts/ReportServer/DataSourceList.aspx?list={ListId}&ID={ItemId}
0x0
0x20
FileType
rsd
352
View Dependent Items
/JCP/article/_layouts/ReportServer/DependentItems.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rsd
353
Compliance Details
javascript:commonShowModalDialog('{SiteUrl}/_layouts/itemexpiration.aspx?ID={ItemId}&List={ListId}', 'center:1;dialogHeight:500px;dialogWidth:500px;resizable:yes;status:no;location:no;menubar:no;help:no', function GotoPageAfterClose(pageid){if(pageid == 'hold') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+'/_layouts/hold.aspx?ID={ItemId}&List={ListId}'); return false;} if(pageid == 'audit') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+'/_layouts/Reporting.aspx?Category=Auditing&backtype=item&ID={ItemId}&List={ListId}'); return false;} if(pageid == 'config') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+'/_layouts/expirationconfig.aspx?ID={ItemId}&List={ListId}'); return false;}}, null); return false;
0x0
0x1
ContentType
0x01
898
Document Set Version History
javascript:SP.UI.ModalDialog.ShowPopupDialog('{SiteUrl}/_layouts/DocSetVersions.aspx?List={ListId}&ID={ItemId}')
0x0
0x0
ContentType
0x0120D520
330
Send To other location
javascript:GoToPage('{SiteUrl}/_layouts/docsetsend.aspx?List={ListId}&ID={ItemId}')
0x0
0x0
ContentType
0x0120D520
350

Comment on Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit

Please note that this forum is mediated to ensure that all comments are relevant to the topic and appropriate for this venue. See PPP Terms of Use and Privacy Policy.

[ Previous  |  Next ]

Information Links

Terms of Use | Privacy Policy | Information for Authors (JCP) | Information for Authors (PCC) | Reprints and Permissions | CNS Job Market | Information for Advertisers | Media Relations | PPP COVID-19 Statement

Help

Contact us | Unsubscribe from Elerts | Customer Service | FAQ | About JCP | About PCC | About Psychiatrist.com

Our Family of Sites

Psychiatrist.com | The Journal of Clinical Psychiatry | The Primary Care Companion | The CME Institute | Strong Veterans
Anonymous